These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 32649325)
41. Racial and Socioeconomic Factors Influence Utilization of Advanced Therapies in Commercially Insured OAB Patients: An Analysis of Over 800,000 OAB Patients. Syan R; Zhang CA; Enemchukwu EA Urology; 2020 Aug; 142():81-86. PubMed ID: 32439551 [TBL] [Abstract][Full Text] [Related]
42. Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: is maintenance treatment necessary? van der Pal F; van Balken MR; Heesakkers JP; Debruyne FM; Bemelmans BL BJU Int; 2006 Mar; 97(3):547-50. PubMed ID: 16469023 [TBL] [Abstract][Full Text] [Related]
43. Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic review. Moossdorff-Steinhauser HF; Berghmans B Neurourol Urodyn; 2013 Mar; 32(3):206-14. PubMed ID: 22907807 [TBL] [Abstract][Full Text] [Related]
44. How I Do It: Transcutaneous tibial nerve stimulation TENSI+ system. Cornu JN; Hashim H; Van Der Aa F; De Nunzio C; Perez VG; Ferreira R; Elterman DS Can J Urol; 2023 Dec; 30(6):11756-11761. PubMed ID: 38104335 [TBL] [Abstract][Full Text] [Related]
45. Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial. Manríquez V; Guzmán R; Naser M; Aguilera A; Narvaez S; Castro A; Swift S; Digesu GA Eur J Obstet Gynecol Reprod Biol; 2016 Jan; 196():6-10. PubMed ID: 26645117 [TBL] [Abstract][Full Text] [Related]
46. Transcutaneous Tibial Nerve Stimulation in the Management of Overactive Bladder: A Scoping Review. Sayner AM; Rogers F; Tran J; Jovanovic E; Henningham L; Nahon I Neuromodulation; 2022 Dec; 25(8):1086-1096. PubMed ID: 35688702 [TBL] [Abstract][Full Text] [Related]
47. Our 11-Year Experience With Percutaneous Tibial Nerve Stimulation in Men and Women for the Treatment of Interstitial Cystitis/Bladder Pain Syndrome. Abdalla AS; Berquist SW; Mohammad A; Dobberfuhl AD Urology; 2023 Dec; 182():73-78. PubMed ID: 37690542 [TBL] [Abstract][Full Text] [Related]
48. Anticholinergic Burden in Patients Treated for Overactive Bladder: Second-Line Therapy with Tibial Nerve Stimulation as a Solution. Satyadev N; Ameen M; Do TH; Wang H Int Urogynecol J; 2024 Jul; 35(7):1375-1379. PubMed ID: 38700729 [TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of the TENSI+ device for posterior tibial nerve stimulation: A multicenter, retrospective study. Cornu JN; Klap J; Thuillier C; Donon L; Meyer F; Even L; Bourguin A; Richard C; Wagner L; Peyronnet B Prog Urol; 2023 Sep; 33(11):541-546. PubMed ID: 37516600 [TBL] [Abstract][Full Text] [Related]
51. Sustained effectiveness of percutaneous tibial nerve stimulation for overactive bladder syndrome: 2-year follow-up of positive responders. Yoong W; Shah P; Dadswell R; Green L Int Urogynecol J; 2013 May; 24(5):795-9. PubMed ID: 22955253 [TBL] [Abstract][Full Text] [Related]
52. Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States. Kraus SR; Shiozawa A; Szabo SM; Qian C; Rogula B; Hairston J Neurourol Urodyn; 2020 Nov; 39(8):2206-2222. PubMed ID: 32827230 [TBL] [Abstract][Full Text] [Related]
53. Effectiveness of Short Term Percutaneous Tibial Nerve Stimulation for Non-neurogenic Overactive Bladder Syndrome in Adults: A Meta-analysis. Wibisono E; Rahardjo HE Acta Med Indones; 2015 Jul; 47(3):188-200. PubMed ID: 26586384 [TBL] [Abstract][Full Text] [Related]
54. Outcome of percutaneous tibial nerve stimulation (PTNS) for fecal incontinence: a prospective cohort study. Hotouras A; Murphy J; Walsh U; Allison M; Curry A; Williams NS; Knowles C; Chan CL Ann Surg; 2014 May; 259(5):939-43. PubMed ID: 23979291 [TBL] [Abstract][Full Text] [Related]
55. Neuromodulative treatment with percutaneous tibial nerve stimulation for intractable detrusor instability: outcomes following a shortened 6-week protocol. Yoong W; Ridout AE; Damodaram M; Dadswell R BJU Int; 2010 Dec; 106(11):1673-6. PubMed ID: 20590544 [TBL] [Abstract][Full Text] [Related]
56. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. Peters KM; Carrico DJ; Wooldridge LS; Miller CJ; MacDiarmid SA J Urol; 2013 Jun; 189(6):2194-201. PubMed ID: 23219541 [TBL] [Abstract][Full Text] [Related]
57. Does response to percutaneous tibial nerve stimulation predict similar outcome to sacral nerve stimulation? Kapriniotis K; Jenks J; Toia B; Pakzad M; Gresty H; Stephens R; Malde S; Sahai A; Greenwell T; Ockrim J Neurourol Urodyn; 2022 Jun; 41(5):1172-1176. PubMed ID: 35481714 [TBL] [Abstract][Full Text] [Related]
58. 8 versus 12 weeks of percutaneous tibial nerve stimulation and response predictors for overactive bladder. Jung CE; Menefee SA; Diwadkar GB Int Urogynecol J; 2020 May; 31(5):905-914. PubMed ID: 31927598 [TBL] [Abstract][Full Text] [Related]
59. The efficacy of posterior tibial nerve stimulation for the treatment of overactive bladder in women: a systematic review. Levin PJ; Wu JM; Kawasaki A; Weidner AC; Amundsen CL Int Urogynecol J; 2012 Nov; 23(11):1591-7. PubMed ID: 22411208 [TBL] [Abstract][Full Text] [Related]
60. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin? Tubaro A; Puccini F; De Nunzio C Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]